Literature DB >> 11145737

Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.

W Feng1, P Webb, P Nguyen, X Liu, J Li, M Karin, P J Kushner.   

Abstract

Estrogen receptor (ER) is activated either by ligand or by signals from tyrosine kinase-linked cell surface receptors. We investigated whether the nonreceptor Src tyrosine kinase could affect ER activity. Expression of constitutively active Src or stimulation of the endogenous Src/JNK pathway enhances transcriptional activation by the estrogen-ER complex and strongly stimulates the otherwise weak activation by the unliganded ER and the tamoxifen-ER complex. Src affects ER activation function 1 (AF-1), and not ER AF-2, and does so through its tyrosine kinase activity. This effect of Src is mediated partly through a Raf/mitogen-activated ERK kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) signaling cascade and partly through a MEKK/JNKK/JNK cascade. Although, as previously shown, Src action through activated ERK stimulates AF-1 by phosphorylation at S118, Src action through activated JNK neither leads to phosphorylation of S118 nor requires S118 for its action. We therefore suggest that the Src/JNK pathway enhances AF-1 activity by modification of ER AF-1-associated proteins. Src potentiates activation functions in CREB-binding protein (CBP) and glucocorticoid receptor interacting protein 1 (GRIP1), and we discuss the possibility that the Src/JNK pathway enhances the activity of these coactivators, which are known to mediate AF-1 action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145737     DOI: 10.1210/mend.15.1.0590

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  25 in total

Review 1.  Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling.

Authors:  Paul H Driggers; James H Segars
Journal:  Trends Endocrinol Metab       Date:  2002-12       Impact factor: 12.015

Review 2.  DNA microarray-based gene expression profiling of estrogenic chemicals.

Authors:  Ryoiti Kiyama; Yun Zhu
Journal:  Cell Mol Life Sci       Date:  2014-01-08       Impact factor: 9.261

3.  A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

Authors:  Linda R Duska; Gina R Petroni; Heather Lothamer; William Faust; Jan H Beumer; Susan M Christner; Anne M Mills; Paula M Fracasso; Sarah J Parsons
Journal:  Cancer Chemother Pharmacol       Date:  2018-12-08       Impact factor: 3.333

4.  Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.

Authors:  Chi-Wai Wong; Christopher McNally; Elliot Nickbarg; Barry S Komm; Boris J Cheskis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

Review 5.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

Review 6.  Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation.

Authors:  Robert D Ward; Nancy L Weigel
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

7.  Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

Authors:  Annabel C Borley; Stephen Hiscox; Julia Gee; Chris Smith; Victoria Shaw; Peter Barrett-Lee; Robert I Nicholson
Journal:  Breast Cancer Res       Date:  2008-12-04       Impact factor: 6.466

Review 8.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

Review 9.  Estrogenic control of mitochondrial function and biogenesis.

Authors:  Carolyn M Klinge
Journal:  J Cell Biochem       Date:  2008-12-15       Impact factor: 4.429

Review 10.  Non-nuclear actions of estrogen: new targets for prevention and treatment of cardiovascular disease.

Authors:  Karen J Ho; James K Liao
Journal:  Mol Interv       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.